Australia, March 21 -- Annexon Inc., owns the trademark (2510945) for 'ANNEXON' till Nov. 22, 2034.
Status: protected:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barre syndrome, macular degeneration, geographic atrophy, Huntington's disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG).], 42 [Pharmaceutical research and development; consulting services in the field of...